Sandra Pérez Baos, Ph.D.

Venture into the realm of biotech entrepreneurship with Geoffrey von Maltzahn, the mastermind behind a multitude of ground-breaking companies that fuse biology and data science to revolutionize human health and sustainability.   Named among Bloomberg's 50 Ones to Watch, Business Insider's 30 Biotech Leaders under 40 and noted as one of Codex's World's Top 50 Innovators, Geoffrey stands as a prominent figure in the realm of biotech entrepreneurship. He has co-founded companies which have massed over $10 billion in market capitalization, including: Flagship Pioneering, Generate:Biomedicines, Quotient Therapeutics and Tessera Therapeutics. As the current CEO of six of these ventures, he is shaping industries with cutting edge technologies like Gene Writing™️ and carbon farming.   Join Joseph McCarthy and Geoffrey for a captivating conversation at the intersection of cutting edge technology, science, entrepreneurship and innovation.   What they discuss:   💡Harnessing the power of AI. 💡The intersection of biology and technology. 💡Entrepreneurial success. 💡The future of human health. 💡Gene editing and personalised medicine. 💡Achieving your peak performance.   LISENT NOW: https://lnkd.in/ehcVkAY8

60

🌟 A heartfelt thank you to the Biopôle Lausanne team for the remarkable event yesterday, co-organized with digitalswitzerland, focusing on the unique challenges digital health startups and scale-ups encounter during the crucial transition from design to deployment. Yesterday's event illuminated the path for many of us in the digital health sector. Tigen Pharma's presentation was a highlight, brilliantly outlining their comprehensive framework. They covered everything from equipment setup, data collection strategies, to the integration of digital twins and business applications. This structured approach ensures consistency across platforms used in CGT autologous clinical trials, which is nothing short of essential. The panel discussion was equally enlightening, exploring critical topics like patient centricity, intellectual property rights, IT infrastructure, and MDR standards. Each panellist brought profound insights that underscored the importance of maintaining focus on these areas as we move from the design and development phase into clinical trials. 🔍 The takeaways from this event are invaluable as we strive to navigate the complex landscape of digital health innovation. Let's keep these lessons in mind and continue to push the boundaries of what's possible in healthcare. 💡 Thank you again to everyone involved for a day full of learning and inspiration! #digitalhealth #innovation #biopôle #digitalswitzerland #healthcaretechnology #clinicaltrials #patientcentricity

40

1 Comment

The majority of companies in LongeVC portfolio are drug discovery companies with a focus on design of small molecules or biologics. Here I grouped the companies by the their therapeutic modality focus: ✔ Small molecules: Rubedo Life Sciences is developing therapeutics to target senescent cells that contribute to age-related diseases. They build an AI-driven platform ALEMBIC™ which is therapeutic agnostic platform aimed at addressing a wide variety of diseases beyond senescence and aging. Freedom Biosciences is developing cutting-edge ketamine therapies for treatment-resistant depression. Here is also Insilico Medicine which I backed as a business angel years ago and quite proud of this project. They apply generative AI platform PandaOmics and Chemistry42 to discover new treatments for COVID-19, pulmonary disease and other conditions. A very productive company that brought 5 candidates to clinical trials in just a couple years, and has almost two dozen preclinical programs going. ✔ Macrocycles (a unique modality, between small molecules and biologics): Unnatural Products Inc. is pairing AI with chemistry and leveraging the power of macrocycles to create treatments for undruggable or hard-to-reach drug targets. ✔ Biologics and therapies Turn Biotechnologies is developing mRNA medicines formulated to instruct specific cells in the body to fight disease or repair damaged tissue. Turn Biotechnologies’ proprietary ERA™ Platform uses mRNA to deliver transcription factors to the epigenome. The platform is safe, fast, efficient and tunable. HelixNano is building what they call the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology. CatenaBio develops novel therapeutics by forming never-before-possible structures, which can modify and combine proteins with ease. They have built a platform for next-generation protein conjugation. Interface Biosciences is developing an AI platform to identify metabolites derived from microorganisms to treat a range of diseases, starting from atopic dermatitis. Ani Biome is a longevity startup pursuing a microbiome-centric approach through personalized bioactive supplements, including AI-driven recommendation engine for patients. Marble Therapeutics deploys genetic solutions to solve skin ageing at the molecular level. As you can see, we are inclined to invest in biotech, although our small molecule companies are very strong. Also, what similarity can you see in most of these companies? First of all, they are platform companies, so called #techbio. Also, almost all are using AI for modeling biology. It is not surprising, because at LongeVC we believe in this kind of tech-driven strategy in drug discovery, so if you are building something like that, reach out and see what we can do together! #technology #venturecapital #drugdiscovery #biotech

123

10 Comments

Talon Biomarkers team looking sharp at #RESI2024. We’ve had a great time meeting with startups and life science investors dicussing how our immune monitoring biomarker discovery platforms can advance their science. Send us a message to learn more! #talonbiomarkers #immunemonitoring #biomarkerdiscovery

5

1 Comment

Insightful angles and cutting-edge vision at the recent mRNA summit! Nicholas Valiante from Innovac Therapeutics and Sophia Lugo from Radar Therapeutics showcased exceptional expertise. In these turbulent times, experience and resilience are key. These outstanding individuals (and companies) are definitely ones to watch! #mRNA #InnovacTherapeutics #RadarTherapeutics

62

Wow - 2 ex-Meta employees launch EvolutionaryScale landing $142m to advance AI in biology. EvolutionaryScale has introduced ESM3, a cutting-edge language model for biology that predicts protein sequences, structures, and functions. This model can simulate millions of years of evolution, generating new proteins with potential applications in medicine, research, and sustainability. ESM3 represents a significant advancement in AI's ability to design and engineer biological systems. There will be comparisons with AlphaFold3, intrigued where this goes... https://lnkd.in/dhtQDtsA #AIinDrugDiscovery #genomics #proteomics

3

1 Comment